VMD-928 / Vm Oncology - LARVOL DELTA

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov) - P1 | N=82 | Recruiting | Sponsor: VM Oncology, LLC | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Adenoid Cystic Carcinoma • Appendix Cancer • Bladder Cancer • Breast Cancer • Cervical Cancer • CNS Tumor • Esophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatology • Lung Cancer • Lymphoma • Mesothelioma • Neuroblastoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Solid Tumor • Thymic Carcinoma • Thymoma • Thymus Cancer • Uterine Cancer • NTRK1

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: VM Oncology, LLC | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Adenoid Cystic Carcinoma • Bladder Cancer • Breast Cancer • Cervical Cancer • Esophageal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatology • Lung Cancer • Lymphoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Solid Tumor • Thymic Carcinoma • Thymus Cancer • Uterine Cancer • NTRK1

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: VM Oncology, LLC | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Adenoid Cystic Carcinoma • Bladder Cancer • Breast Cancer • Cervical Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatology • Lung Cancer • Lymphoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Solid Tumor • Thymic Carcinoma • Thymus Cancer • NTRK1

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: VM Oncology, LLC | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Adenoid Cystic Carcinoma • Cervical Cancer • Colon Cancer • Colorectal Cancer • Gallbladder Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatology • Leiomyosarcoma • Lung Cancer • Lymphoma • Mesothelioma • Oncology • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thymic Carcinoma • Thymoma • Thymus Cancer • NTRK1

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: VM Oncology, LLC | N=54 ➔ 74 | Trial completion date: Dec 2022 ➔ Jun 2024 | Trial primary completion date: Jun 2022 ➔ Dec 2023

Enrollment change • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Adenoid Cystic Carcinoma • Cervical Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatocellular Cancer • Hepatology • Leukemia • Lung Cancer • Lymphoma • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thymic Carcinoma • Thymoma • Thymus Cancer • NTRK1

[VIRTUAL] First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma. (ASCO 2021) - P1 | "This is clinically validated by demonstrated efficacy of ATP-competitive pan-TrkA/B/C inhibitors, larotrectinib and entrectinib for treatment of advanced solid tumors harboring NTRK1/2/3 gene fusions . VMD-928 was well tolerated with mainly gastrointestinal side effects . The recommended phase 2 dose (RP2D) is 600 mg twice (1200 mg) per day . The study is currently accruing in expansion cohorts to evaluate efficacy in biomarker-selected patients with tumors of TrkA protein overexpression ."

Clinical • Adenoid Cystic Carcinoma • Biliary Cancer • Cholangiocarcinoma • Fatigue • Gastrointestinal Cancer • Gastrointestinal Disorder • Head and Neck Cancer • Hematological Malignancies • Hepatology • Lung Cancer • Lymphoma • Mesothelioma • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Targeted Protein Degradation • Thymic Carcinoma • Thymus Cancer • NTRK3

Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma (clinicaltrials.gov) - P1; N=54; Recruiting; Sponsor: VM Oncology, LLC; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Jun 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Cervical Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatocellular Cancer • Hepatology • Leukemia • Lung Cancer • Lymphoma • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thymus Cancer • NTRK • NTRK1